STOCK TITAN
  1. Home
  2. Sec-filings
  3. VMD
  4. [Form 4] VIEMED HEALTHCARE, INC. Insider Trading Activity

Viemed Healthcare (VMD) VP granted RSUs and phantom share units

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Viemed Healthcare vice president of sales Jerome Cambre reported equity compensation and related tax transactions in company stock. On January 17, 2026, previously granted awards vested, resulting in the acquisition of 8,525 common shares from restricted stock units and 2,132 common shares tied to phantom share units. To cover taxes from the vesting, 2,784 shares and a separate 2,132-share block were disposed of at a per-share value of $7.33, leaving Cambre with 89,932 common shares held directly.

On January 19, 2026, Cambre received new grants of 40,676 restricted stock units and 10,169 phantom share units. Each restricted stock unit represents a contingent right to receive one common share, and both the new RSU and phantom share awards vest in three equal annual installments beginning on the first anniversary of their respective grant dates.

Positive

  • None.

Negative

  • None.
Insider Cambre Jerome
Role Vice President of Sales
Type Security Shares Price Value
Grant/Award Restricted Stock Units 40,676 $0.00 --
Grant/Award Phantom Share Units 10,169 $0.00 --
Exercise Restricted Stock Units 8,525 $0.00 --
Exercise Phantom Share Units 2,132 $0.00 --
Exercise Common Shares 8,525 $0.00 --
Tax Withholding Common Shares 2,784 $7.33 $20K
Exercise Common Shares 2,132 $0.00 --
Disposition Common Shares 2,132 $7.33 $16K
Holdings After Transaction: Restricted Stock Units — 40,676 shares (Direct); Phantom Share Units — 10,169 shares (Direct); Common Shares — 92,716 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units. Per share value is based on the market closing price of the common shares for January 16, 2026. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash. Restricted Stock Units (RSUs) granted to reporting person on January 17, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date. Represents an award granted on January 17, 2023 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date. Restricted Stock Units (RSUs) granted to reporting person on January 19, 2026, which vest in three equal annual installments beginning on the first anniversary of the grant date. Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date. Represents an award granted on January 19, 2026 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cambre Jerome
(Last) (First) (Middle)
625 E. KALISTE SALOOM RD.
(Street)
LAFAYETTE LA 70508
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Vice President of Sales
3. Date of Earliest Transaction (Month/Day/Year)
01/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 01/17/2026 M 8,525 A (1) 92,716 D
Common Shares 01/17/2026 F 2,784(2) D $7.33(3) 89,932 D
Common Shares 01/17/2026 M 2,132 A (4) 92,064 D
Common Shares 01/17/2026 D 2,132 D $7.33(3) 89,932 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 01/17/2026 M 8,525 (5) 01/17/2026 Common Shares 8,525 $0 0 D
Phantom Share Units (4) 01/17/2026 M 2,132 (6) 01/17/2026 Common Shares 2,132 (4) 0 D
Restricted Stock Units (1) 01/19/2026 A 40,676 (7) 01/19/2029 Common Shares 40,676 $0 40,676 D
Phantom Share Units (8) 01/19/2026 A 10,169 (9) 01/19/2029 Common Shares 10,169 $0 10,169 D
Explanation of Responses:
1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.
2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.
3. Per share value is based on the market closing price of the common shares for January 16, 2026.
4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.
5. Restricted Stock Units (RSUs) granted to reporting person on January 17, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date.
6. Represents an award granted on January 17, 2023 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
7. Restricted Stock Units (RSUs) granted to reporting person on January 19, 2026, which vest in three equal annual installments beginning on the first anniversary of the grant date.
8. Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date.
9. Represents an award granted on January 19, 2026 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
Remarks:
/s/ Jesse Bergeron, Attorney-in-Fact 01/21/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in Viemed Healthcare (VMD) involved in this Form 4?

The insider is Jerome Cambre, who serves as Vice President of Sales at Viemed Healthcare, Inc.. The filing covers his transactions and awards in company equity and related units.

What equity awards did Jerome Cambre receive from Viemed Healthcare (VMD) in January 2026?

On January 19, 2026, Jerome Cambre received 40,676 restricted stock units and 10,169 phantom share units. Both awards vest in three equal annual installments beginning on the first anniversary of the grant date.

How many Viemed Healthcare (VMD) common shares does Jerome Cambre hold after the reported transactions?

Following the transactions on January 17, 2026, Jerome Cambre beneficially owned 89,932 common shares of Viemed Healthcare directly.

What transactions occurred when Jerome Cambre’s prior Viemed Healthcare awards vested?

On January 17, 2026, the vesting of prior awards led to the acquisition of 8,525 common shares from restricted stock units and 2,132 common shares related to phantom share units. To satisfy tax obligations and cash settlement mechanics, blocks of 2,784 shares and 2,132 shares were disposed of at a per-share value of $7.33.

How do Viemed Healthcare (VMD) restricted stock units work for Jerome Cambre?

Each restricted stock unit (RSU) represents a contingent right to receive one common share of Viemed Healthcare. The RSUs granted on January 17, 2023 and January 19, 2026 vest in three equal annual installments starting on the first anniversary of each grant date.

What are Viemed Healthcare (VMD) phantom share units reported in this Form 4?

The phantom share units are cash-settled awards under Viemed Healthcare’s Phantom Share Unit Plan. Each phantom share is the economic equivalent of one common share and represents a right to receive the cash value of one share, determined based on the company’s share price on the vesting date.